E-LIB Suche - Ergebnisse für: Tahara, Atsuo

1

Withdrawn: SGLT2 inhibitor ipragliflozin poses a low risk o..:

Tahara, Atsuo
Clinical and Experimental Pharmacology and Physiology. 49 (2022) 6 - p. 699-699 , 2022

Link: https://doi.org/10.1111/..

2

Effects of neurokinin 3 receptor antagonist fezolinetant on..:

Tahara, Atsuo ; Takamatsu, Hajime ; Ohtake, Akiyoshi..
European Journal of Pharmacology. 905 (2021) - p. 174207 , 2021

Link: https://doi.org/10.1016/..

3

Effects of SGLT2 inhibitor ipragliflozin alone and combined..:

Tahara, Atsuo
European Journal of Pharmacology. 901 (2021) - p. 174076 , 2021

Link: https://doi.org/10.1016/..

4

SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effe..:

Tahara, Atsuo
European Journal of Pharmacology. 910 (2021) - p. 174486 , 2021

Link: https://doi.org/10.1016/..

5

Therapeutic effects of interleukin-1 receptor-associated ki..:

Kondo, Mitsuhiro ; Tahara, Atsuo ; Hayashi, Kazumi...
Naunyn-Schmiedeberg's Archives of Pharmacology. 393 (2020) 7 - p. 1197-1209 , 2020

Link: https://doi.org/10.1007/..

6

In Vitro Pharmacological Profile of Ipragliflozin, a Sodium..:

Takasu, Toshiyuki ; Yokono, Masanori ; Tahara, Atsuo.
Biological and Pharmaceutical Bulletin. 42 (2019) 3 - p. 507-511 , 2019

Link: https://doi.org/10.1248/..

7

SGLT2 inhibitor ipragliflozin alone and combined with piogl..:

Tahara, Atsuo ; Takasu, Toshiyuki
Physiological Reports. 7 (2019) 22 - p. , 2019

Link: https://doi.org/10.14814..

8

Antidiabetic and antiobesity effects of SGLT2 inhibitor ipr..:

Tahara, Atsuo ; Takasu, Toshiyuki ; Yokono, Masanori..
European Journal of Pharmacology. 818 (2018) - p. 545-553 , 2018

Link: https://doi.org/10.1016/..

9

Effects of the SGLT2 inhibitor ipragliflozin on various dia..:

Tahara, Atsuo ; Takasu, Toshiyuki
Naunyn-Schmiedeberg's Archives of Pharmacology. 391 (2018) 4 - p. 395-406 , 2018

Link: https://doi.org/10.1007/..

10

Prevention of progression of diabetic nephropathy by the SG..:

Tahara, Atsuo ; Takasu, Toshiyuki
European Journal of Pharmacology. 830 (2018) - p. 68-75 , 2018

Link: https://doi.org/10.1016/..

11

Effects of the SGLT2 inhibitor ipragliflozin on food intake..:

Tahara, Atsuo ; Kondo, Yoshinori ; Takasu, Toshiyuki.
Biomedicine & Pharmacotherapy. 105 (2018) - p. 1033-1041 , 2018

Link: https://doi.org/10.1016/..

12

Antidiabetic effects of SGLT2 inhibitor ipragliflozin in ty..:

Tahara, Atsuo ; Takasu, Toshiyuki
Life Sciences. 197 (2018) - p. 80-90 , 2018

Link: https://doi.org/10.1016/..

13

Characterization and comparison of SGLT2 inhibitors: Part 3..:

Tahara, Atsuo ; Takasu, Toshiyuki ; Yokono, Masanori..
European Journal of Pharmacology. 809 (2017) - p. 163-171 , 2017

Link: https://doi.org/10.1016/..

14

Characterization and comparison of sodium-glucose cotranspo..:

Tahara, Atsuo ; Takasu, Toshiyuki ; Yokono, Masanori..
Journal of Pharmacological Sciences. 130 (2016) 3 - p. 159-169 , 2016

Link: https://doi.org/10.1016/..

15

Characterization and comparison of sodium-glucose cotranspo..:

Tahara, Atsuo ; Takasu, Toshiyuki ; Yokono, Masanori..
Journal of Pharmacological Sciences. 131 (2016) 3 - p. 198-208 , 2016

Link: https://doi.org/10.1016/..